If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-17. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
=== Neodymium === The rare earth element Neodymium is extracted by di(2-ethyl-hexyl)phosphoric acid into hexane by an ion exchange mechanism. Neodymium can also be separated from dysprosium through selective precipitation of dysprosium with Cyanex 272 when the HNO3 concentration was 0.001 mol/L.
=== The hypercycle === In the early 1970s, Manfred Eigen and Peter Schuster examined the transient stages between the molecular chaos and a self-replicating hypercycle in a prebiotic soup. In a hypercycle, the information storing system (possibly RNA) produces an enzyme, which catalyzes the formation of another information system, in sequence until the product of the last aids in the formation of the first information system. Mathematically treated, hypercycles could create quasispecies, which through natural selection entered into a form of Darwinian evolution. A boost to hypercycle theory was the discovery of ribozymes capable of catalyzing their own chemical reactions. The hypercycle theory requires the existence of complex biochemicals, such as nucleotides, which do not form under the conditions proposed by the Miller–Urey experiment.
Moreover, if we move in the direction of making machines which learn and whose behavior is modified by experience, we must face the fact that every degree of independence we give the machine is a degree of possible defiance of our wishes. In 1988, Blay Whitby published a book outlining the need for AI to be developed along ethical and socially responsible lines. From 2008 to 2009, the Association for the Advancement of Artificial Intelligence (AAAI) commissioned a study to explore and address potential long-term societal influences of AI research and development. The panel was generally skeptical of the radical views expressed by science-fiction authors but agreed that "additional research would be valuable on methods for understanding and verifying the range of behaviors of complex computational systems to minimize unexpected outcomes". In 2011, Roman Yampolskiy introduced the term "AI safety engineering" at the Philosophy and Theory of Artificial Intelligence conference, listing prior failures of AI systems and arguing that "the frequency and seriousness of such events will steadily increase as AIs become more capable". In 2014, philosopher Nick Bostrom published the book Superintelligence: Paths, Dangers, Strategies. He has the opinion that the rise of AGI has the potential to create various societal issues, ranging from the displacement of the workforce by AI, manipulation of political and military structures, to even the possibility of human extinction.
== Bioequivalence == In determining bioequivalence between two products such as a commercially available Branded product and a potential to-be-marketed Generic product, pharmacokinetic studies are conducted whereby each of the preparations are administered in a cross-over study (sometimes parallel study, when a cross-over study is not feasible) to volunteer subjects, generally healthy individuals but occasionally in patients. Serum/plasma samples are obtained at prescribed times and assayed for parent drug (or occasionally metabolite) concentration. Occasionally, blood concentration levels are neither feasible or possible to compare the two products (e.g. inhaled corticosteroids), then pharmacodynamic endpoints rather than pharmacokinetic endpoints (see below) are used for comparison. For a pharmacokinetic comparison, the plasma concentration data are used to assess key pharmacokinetic parameters such as area under the curve (AUC), peak concentration (Cmax), time to peak concentration (tmax), and absorption lag time (tlag). Testing should be conducted at several different doses, especially when the drug displays non-linear pharmacokinetics. In addition to data from bioequivalence studies, other data may need to be submitted to meet regulatory requirements for bioequivalence. Such evidence may include:
Mothers who take certain recreational drugs should not breastfeed, however, most medications are compatible with breastfeeding. Available evidence indicates that it is unlikely that COVID-19 can be transmitted through breast milk. Smoking tobacco and consuming limited amounts of alcohol or coffee are not reasons to avoid breastfeeding.
Sources: en.wikipedia.org
J. League Manager of the Year: 1995 Onze d'Or Coach of The Year: 2000, 2002, 2003, 2004 Premier League Manager of the Season: 1997–98, 2001–02, 2003–04 LMA Manager of the Year: 2001–02, 2003–04 BBC Sports Personality of the Year Coach Award: 2002, 2004 London Football Awards – Outstanding Contribution to a London Club: 2015 World Soccer Manager of the Year: 1998 FWA Tribute Award: 2005 English Football Hall of Fame: 2006 France Football Manager of the Year: 2008 IFFHS World Coach of the Decade: 2001–2010 Facebook FA Premier League Manager of the Year: 2014–15 Premier League Manager of the Month: March 1998, April 1998, October 2000, April 2002, September 2002, August 2003, February 2004, August 2004, September 2007, December 2007, February 2011, February 2012, September 2013, March 2015, October 2015 France Football 32nd Greatest Manager of All Time: 2019 World Soccer 36th Greatest Manager of All Time: 2013 Laureus Lifetime Achievement Award: 2019 Premier League Hall of Fame: 2023 Orders
Like all governing institutions in mainland China, Ningxia has a parallel party-government system, in which the CCP Ningxia Regional Committee secretary outranks the government chairman. The CCP Ningxia Regional Committee acts as the top policy-formulation body, and has control over the Ningxia Hui Autonomous Region People's Government.
The most common first symptom of all snakebites is an overwhelming fear, which may contribute to other symptoms, and may include nausea and vomiting, diarrhea, vertigo, fainting, tachycardia, and cold, clammy skin. Snake bites can have a variety of different signs and symptoms depending on their species. Dry snakebites and those inflicted by a non-venomous species may still cause severe injury. The bite may become infected from the snake's saliva. The fangs sometimes harbor pathogenic microbial organisms, including Clostridium tetani, and may require an updated tetanus immunization. Most snakebites, from either a venomous or a non-venomous snake, will have some type of local effect. Minor pain and redness occur in over 90 percent of cases, although this varies depending on the site. Bites by vipers and some cobras may be extremely painful, with the local tissue sometimes becoming tender and severely swollen within five minutes. This area may also bleed and blister and may lead to tissue necrosis. Other common initial symptoms of pit viper and viper bites include lethargy, bleeding, weakness, nausea, and vomiting. Symptoms may become more life-threatening over time, developing into hypotension, tachypnea, severe tachycardia, severe internal bleeding, altered sensorium, kidney failure, and respiratory failure. Bites by some snakes, such as the kraits, coral snake, Mojave rattlesnake, and the speckled rattlesnake, may cause little or no pain, despite their serious and potentially life-threatening venom.
Israel: Trump's plan was met with support in Israel with prime minister Benjamin Netanyahu saying that he was committed to the realization of the plan, rejecting the Palestinian Authority's or Hamas' governance of Gaza. Trump's proposal to resettle Palestinians from Gaza was supported by Netanyahu, Israeli Defense Minister Israel Katz, Israeli opposition leader Yair Lapid, and the majority of the Israeli public. Jordan: King Abdullah II of Jordan rejected President Trump's proposal for Jordan to absorb Palestinians living in Gaza. There are already more than 2 million Palestinian refugees in Jordan who fled due to the Arab–Israeli wars. Egypt: Egypt rejected American plans to annex Gaza and did not agree to take into Egypt displaced Palestinians. Instead, the Egyptian government responded by proposing a counter-offer of Egypt-led reconstruction of the strip. Egypt also signalled that the ethnic cleansing of Gaza would lead to the end of the Egypt–Israel peace treaty. Syria: Syrian president Ahmed al-Sharaa criticized Trump's plan, calling it a "serious crime that will ultimately fail." In an interview with The Rest Is Politics, al-Sharaa claimed that "no power can drive people from their land" and that "over 80 years of this conflict, all attempts to displace [Palestinians] have failed; those who left have regretted their decision. The Palestinian lesson that every generation has learned is the importance of holding on to their land." Turkey: Turkish president Erdogan rejected Trump's plan, highlighting that it would be a major threat to world peace.
=== Early research === In 1966, for the first time, Ammann and Richard E. Stiehm documented Immunoglobulin A (IgA) as the major immunoglobulin class in breastmilk, present in high concentrations in colostrum mature breastmilk. They postulated that the protection afforded to infants by breast-feeding was a result of exposure to local antibodies contained within IgA rather than absorption of maternal antibody into these infants circulation. Ammann, Stiehm and James D. Cherry identified that there are elevated levels of Immunoglobulin M (IgM) in the cord blood of newborn infants born with the congenital rubella syndrome. This was a major step forward in understanding the fetal immune response and developing diagnostic tools to differentiate between in utero infection with infectious agents such as rubella, toxoplasmosis and cytomegalovirus from infections acquired following birth. In 1973, Ammann led his research team to perform the first successful reconstitution of T-cell immunity in a patient with severe combined immunodeficiency. This was achieved through fetal thymus transplantation. This study demonstrated that the thymus holds only the potential of developing T cells and will not result in reconstitution of B cell immunity as was subsequently shown by others who utilized bone marrow transplantation, which contained multi-potential stem cells.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.